For transplant-ineligible patients with a broad range of characteristics, consider targeted immunotherapy with MONJUVI for treatment of R/R DLBCL in the second line1

Image of patient who progressed within 12 months and wants to stay local for treatment

Not an actual patient.

Profile in Practice #1:

Patient who progressed within 12 months*
and wants to stay local for treatment

Learn more from an expert

Play Video
Patient who progressed within 12months* and wants to stay local

Treatment History

  • PR achieved after 4 cycles of R-CHOP; maintained through completion of first-line therapy1
  • Disease progressed after a quick relapse—4 months following first-line therapy

Treatment Considerations

Disease severity2

  • IPI: 3 (intermediate-high to high risk)
  • Ann Arbor Stage: 3

Performance status/age2,3

  • ECOG: 1
  • Aged 65 years

Comorbidities

  • Hypertension4

Patient considerations

  • Eager to initiate treatment
  • Declined ASCT based on
    • Lack of support system
    • Preference to stay with current care team, but still seeking further treatment

This is a hypothetical patient profile.

R-CHOP=rituximab/cyclophosphamide/hydroxydaunomycin/oncovin/prednisone; IPI=International Prognostic Index; ECOG=Eastern Cooperative Oncology Group; ASCT=autologous stem cell transplant.

*Primary refractory patients were defined in L-MIND as those whose DLBCL relapsed or progressed after at least 3 months from completion of prior CD20-containing therapy.5

Image of patient with chemorefractory disease

Not an actual patient.

Profile in Practice #2:

Patient with chemorefractory disease

Learn more from an expert

Play Video
Patient with chemorefractory disease

Treatment History

  • First-line treatment: 6 cycles of R-CHOP1
  • CR achieved following R-CHOP; progressed 6 months after completion of first-line therapy1
  • Salvage chemotherapy failed to induce a response, ineligible for ASCT, and performance status declined to ECOG 2 following chemotherapy3

Treatment Considerations

Disease severity2,5

  • IPI: 3 (intermediate-high to high risk)
  • Ann Arbor Stage: 3
  • Elevated LDH
  • Bulky disease

Performance status/age2,3

  • ECOG: 1
  • Aged 68 years

Comorbidities

  • Hypothyroidism

Patient considerations

  • Lives in a rural area
  • Wants to stay local and receive outpatient treatment
  • Financial considerations are important

This is a hypothetical patient profile.

R-CHOP=rituximab/cyclophosphamide/hydroxydaunomycin/oncovin/prednisone; CR=complete response rate; ASCT=autologous stem cell transplant; ECOG=Eastern Cooperative Oncology Group; IPI=International Prognostic Index; LDH=lactate dehydrogenase.

Image of patient with R/R disease and comorbidities

Not an actual patient.

Profile in Practice #3:

Patient with R/R disease and comorbidities

Learn more from an expert

Play Video
Patient with R/R disease and comorbidities

Treatment History

  • First-line treatment: 6 cycles of frontline R-mini-CHOP1
  • Complete response achieved following R-mini-CHOP1
  • Relapsed disease with symptoms 2 years after achieving CR
  • Ineligible for ASCT due to comorbidities3

Treatment Considerations

Disease severity2

  • IPI: 2 (low to low-intermediate risk)
  • Ann Arbor Stage: 3

Performance status/age2,3

  • ECOG: 2
  • Aged 75 years

Comorbidities4

  • Hypertension
  • Atrial fibrillation (with pacemaker)

Patient considerations

  • Looking for tumor reduction

This is a hypothetical patient profile.

R-CHOP=rituximab/cyclophosphamide/hydroxydaunomycin/oncovin/prednisone; CR=complete response rate; ASCT=autologous stem cell transplant; IPI=International Prognostic Index; ECOG=Eastern Cooperative Oncology Group.